Only recently, the pharma company Sanofi has announced to discontinue the global clinical development program of tusamitamab ravtansine based an interim analysis of the Phase 3 CARMEN-LC03 trial evaluating tusamitamab ravtansine as monotherapy compared to docetaxel in previously treated patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors express high levels of CEACAM5. This evidence concerns the gene CEACAM5 and non-small cell squamous lung carcinoma.